Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Wednesday, Septemeber 9, 2026
Encoded Therapeutics’ $275 Million Series F
Solstice Oncology’s $225 Million Series A
Caspian Therapeutics’ $50 Million Financing
Tuesday, Septemeber 8, 2026
Korsana’s $380 Million Private Placement
BrainChild Bio’s $116 Million Series A
Moonwalk’s $70 Million Series B
PDS Biotech’s $12 Million Private Placement
Seraxis’s Acquisition of Sernova
Thursday, Septemeber 3, 2026
Superluminal’s $60 Million Series B
Wednesday, Septemeber 2, 2026
Typewriter’s $56 Million Series A
N-Power Medicine’s $32 Million Series B
Tuesday, Septemeber 1, 2026
CytoDyn’s $17 Million Venture Financing
Amyl’s $9 Million Series A Extension
Monday, August 31, 2026
PMV Pharma’s $50.8 Million Public Offering
Kazia Therapeutics’ $40 Million Public Offering
EIT Pharma’s $35 Million Series A
Convergen’s $15 Million Seed Financing
Lilly’s Acquisition of Merida Biosciences
Friday, August 28, 2026
Quoin Pharmaceuticals’ $30.8 Million Private Placement
BioLineRx’s $4 Million Registered Direct Offering and Private Placement
Thursday, August 27, 2026
AusperBio’s $120 Million Series C
Tuesday, August 25, 2026
Immatics’s $150 Million Public Offering
Airway’s $24 Million Series E-2 Financing
Revier’s $7 Million Seed Financing
UNIVO’s Acquisition of NeuroNOS
Friday, August 21, 2026
Ambros Therapeutics’ $150 Million Concurrent Private Placement
Gossamer Bio’s $25 Million Structured Private Placement
Thursday, August 20, 2026
Lobe’s $2 Million Private Placement
Wednesday, August 19, 2026
Amylyx Pharmaceuticals’ $500 Million Upsized Public Offering
Kynexis’s $70 Million Series A Extension
Network’s $50 Million Venture Financing
Edesa Biotech’s $25 Million Public Offering
KaliVir Immunotherapeutics’ $14 Million Series A Extension
Tuesday, August 18, 2026
NeuroThera Labs’ $4 Million Private Placement
BioMarin’s Acquisition of Alesta Therapeutics
Monday, August 17, 2026
Slate’s $245 Million Private Placement
Leal Therapeutics’ $30 Million Series A Second Close
AB Science’s $16 Million Private Placement
Friday, August 14, 2026
BridgeBio’s $390 Million Public Offering
Skye’s $68 Million Reverse Merger
Daré Bioscience’s $6 Million Registered Direct Offering
Thursday, August 13, 2026
AbCellera’s $200 Million Public Offering
MapLight’s $150 Million Private Placement
Zentalis’ $80.5 Million Public Offering
Curis’s $6 Million Public Offering
Aptevo’s $4 Million Announces Warrants Exercise
Wednesday, August 12, 2026
Bridge’s $110 Million Series C
InduPro’s $77 Million Series B
Boulevard’s $65 Million Financing
Outlook’s $55 Million Public Offering
Lilly’s $50 Million Acquisition of Sangamo Platform Assets
Rakovina Therapeutics’ $1 Million First Tranche
Tuesday, August 11, 2026
Silence’s $175 Million Public Offering
Vaderis’s $152 Million Series B
Epicrispr’s $90 Million Series C
Vogenx’s $81.3 Million Initial Public Offering
Infinimmune’s $75 Million Series A
K2’s $50 Million Seed Financing
Apollomics’s $10 Million Private Placement
Silexion’s $2 Million Public Offering
Boehringer Ingelheim’s Acquisition of Evax
Monday, August 10, 2026
Jazz’s $820 Million Acquisition of Actio
Avere’s $500 Million Private Placement
Replimune’s $150 Million Public Offering
Aureka’s $100 Million Series B
Remedium’s $10 Million Series A
MindMaze’s $10 Million Equity Financing
Hopstem’s Series C First Closing
Thursday, August 6, 2026
Tarsus’s $450 Million Acquisition of Alkeus
Latigo’s $346 Million Initial Public Offering
LifeMine’s $188 Million Series E
BlossomHill’s $150 Million Initial Public Offering
Tarsus’s $125 Million Private Placement
Vedanta’s $40 Million Financing
Ensysce’s $22 Million Private Placement
Wednesday, August 5, 2026
Braveheart’s $383 Million Initial Public Offering
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.